Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Chinese PLA General Hospital
Sponsor:
Collaborator:
Navy General Hospital, Beijing
Information provided by (Responsible Party):
Li Yu, Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT01758367
First received: December 27, 2012
Last updated: August 29, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)